Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study

NCT03480568 is registered in ClinicalTrials.gov with Baylor Research Institute as lead sponsor.

NCT NCT03480568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03480568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
Lead sponsor
Baylor Research Institute
Phase
Phase 3
Overall status
Recruiting
Start date
May 1, 2018
Completion date
December 31, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic disease, hemodialysis, hypercholesterolemia, peritoneal dialysis